Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $2.97B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.93M
Average 1.71M
DYN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Dyne Therapeutics, Inc.NASDAQ: DYN
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $29.49M rose 78.1% year over year, ahead of the +50.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 20.9% from the prior quarter. Over 3 fiscal years it compounded at +35.3% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +11.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $29.49M+20.9% QoQ
- Last fiscal yearDec 2025
- $69.85M+11.8% YoY
- LTMJun 2026
- $91.25M+50.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +78.1% | -100.0% | -178.1 pp |
| 1 year | +11.8% | -100.0% | -111.8 pp |
| 3-year CAGR | +35.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 69.85M USD
- Year-over-year change
- +11.8%
- 4-year CAGR
- +24.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 69.85M | +11.8% |
| FY2024 | 2024-12-31 | 62.48M | +99.0% |
| FY2023 | 2023-12-31 | 31.4M | +11.3% |
| FY2022 | 2022-12-31 | 28.2M | -1.8% |
| FY2021 | 2021-12-31 | 28.72M | — |
Selling, General & Admin vs competitors
How DYN compares with its peers on the latest reported figures
- DYN's LTM Jun 2026 selling, general & admin of $91.25M is the 4th highest of the 11 companies compared; the peer median is $56.06M.
- Its year-over-year change of +50.5% is the 3rd highest of 11, against a peer median of +13.5%.
- Over three fiscal years its annual growth of +35.3% compares with a peer median of +14.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $584.98M | +66.3% | +37.9% | 61.0% | |
| LTM Mar 2026 | $467.04M | -17.3% | +2.0% | 21.4% | |
| LTM Jun 2026 | $351.33M | +8.3% | +2.1% | 34.8% | |
| LTM Jun 2026 | $91.25M | +50.5% | +35.3% | — | |
| LTM Mar 2026 | $79.08M | +23.9% | +14.3% | 110.1% | |
| LTM Mar 2026 | $71.21M | +35.2% | +19.9% | 222.0% | |
| LTM Mar 2026 | $40.91M | +18.8% | +10.3% | — | |
| LTM Mar 2026 | $40.9M | +4.0% | +10.2% | 712.8% | |
| LTM Mar 2026 | $26.76M | +58.7% | +29.7% | — | |
| LTM Mar 2026 | $22.56M | +1.9% | +16.6% | — | |
| LTM Mar 2026 | $19.82M | +7.4% | +14.2% | — | |
| Peer median (excluding DYN) | $56.06M | +13.5% | +14.2% | 85.5% | |
Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.46M | 2.24M | 2.05M |
| Gross Profit | 0 | 0 | (2.46M) | (2.24M) | (2.05M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
| Selling, General & Admin | 28.72M | 28.2M | 31.4M | 62.48M | 69.85M |
| Operating Expenses | 150.03M | 170.96M | 239.7M | 341.64M | 466.14M |
| Depreciation & Amortization | 1.09M | 1.68M | 1.67M | 1.67M | 2.05M |
| EBITDA | (148.2M) | (163.5M) | (234.26M) | (315.75M) | (437.97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (150.03M) | (170.96M) | (242.16M) | (343.89M) | (468.18M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 742K | 2.92M | 7.64M | 26.92M | 29.86M |
| Interest Expense | 0 | 2.92M | 0 | 0 | 6.19M |
| Other Income / Expenses | 734K | 2.86M | 6.23M | 26.47M | 21.97M |
| Income Before Tax | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| EPS (Diluted) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| Weighted Avg Shares | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M |
| Weighted Avg Shares (Diluted) | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M |
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$15.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.